Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Jasper Therapeutics Q3 2026 Results: Net Loss of $144M, Loss Widens

Jasper Therapeutics reported a significant net loss of $148.4 million for the nine months ended September 30, 2026, primarily driven by a $129.5 million charge for acquired in-process research and development. Despite the loss, the company strengthened its liquidity through a financing and acquisition, ending the period with $135.3 million in cash and cash equivalents.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue8.0—
Net income-144.5-18.7
EPS (diluted, $ a share)$-10.19$-32.08

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: JSPR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Jasper Therapeutics, Inc.: key numbers

Share price
$11.77Close, Nov 16
Market cap
$13.1M
Shares outstanding
1.11MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Jasper Therapeutics, Inc.

All →
8:01 AM ET 8-K
Financial Results

Jasper Therapeutics Financial Results

Jasper Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided a corporate update following its acquisition of Kira Pharmaceuticals. The company highlighted progress in its Phase 2 renal basket study for vensobafusp alfa (KP104), including completed enrollment in the IgA nephropathy cohort and the dosing of the first patient with IC-MPGN.

“We have made progress advancing our development programs in recent months following our acquisition of Kira Pharmaceuticals, highlighted by the recent completion of enrollment in the first cohort of our Phase 2 renal basket study evaluating vensobafusp alfa (KP104) in patients with IgA nephropathy (IgAN).”

Jeet Mahal, President and Chief Executive Officer of Jasper

“We believe that the bifunctional ability of vensobafusp alfa to inhibit both the alternative and terminal complement pathways may provide the potential for differentiated onset and efficacy in complement driven diseases, and we look forward to presenting interim data from the IgAN cohort in the fourth quarter of 2026 and additional updates from our pipeline programs in 2027.”

Jeet Mahal, President and Chief Executive Officer of Jasper
4:32 PM ET 8-K
Shareholder Meeting

Jasper Therapeutics Shareholder Meeting

Jasper Therapeutics convened and then adjourned its special meeting of stockholders due to the lack of a quorum. The meeting has been rescheduled to reconvene virtually on December 1, 2026, with no changes to the proposals or the record date.

8:05 AM ET 8-K
Stock Buyback

Jasper Therapeutics Announces $2.76M Stock Buyback

Jasper Therapeutics completed a tender offer to repurchase 8,510,658 of its outstanding warrants at a price of $0.324 per warrant. The company will pay an aggregate of approximately $2.76 million in cash for the tendered warrants, which represent roughly 68.94% of the outstanding warrants issued in September 2025.

Value
$2.76M
8:12 AM ET 8-K
Reverse Stock Split

Jasper Therapeutics Reverse Stock Split

Jasper Therapeutics announced a 1-for-30 reverse stock split of its common stock, effective November 6, 2026. The split will reduce the number of outstanding shares from approximately 33.3 million to 1.1 million to increase the per-share trading price on the Nasdaq Capital Market. The authorized number of shares remains unchanged at 490 million, resulting in an increase in authorized but unissued shares available for future use.

8:00 AM ET 8-K
Clinical Trial Data

Jasper Therapeutics Clinical Trial Data

Jasper Therapeutics completed enrollment for the IgA nephropathy (IgAN) cohort of its Phase 2 basket study evaluating vensobafusp alfa (KP104). The company expects to report initial interim data from this study by year-end 2026 and plans to expand the study to include patients with focal segmental glomerulosclerosis (FSGS) in early 2027.

8:06 AM ET 8-K
Stock Buyback

Jasper Therapeutics Announces $4M Stock Buyback

Jasper Therapeutics has commenced a cash tender offer to repurchase all 12,345,707 of its outstanding warrants issued in September 2025 at a price of $0.324 per warrant. The company expects to pay approximately $4.0 million if all warrants are tendered, aiming to reduce potential share dilution and simplify its capital structure.

Value
$4M
Term
through Nov 6, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.